Effects of Intravenous Administration of Vancomycin on Peritonitis in a Patient on Peritoneal Dialysis

Area of Science:

• Nephrology
• Infectious Diseases
• Pharmacokinetics

Background:

• Peritoneal dialysis-associated peritonitis is a common complication.
• Intraperitoneal vancomycin is the standard treatment but may be unavailable or off-label in some regions.
• Limited pharmacokinetic data exists for intravenous vancomycin dosing in this context.

Purpose of the Study:

• To evaluate the viability of intravenous vancomycin for treating peritoneal dialysis-associated peritonitis.
• To propose pragmatic therapeutic drug monitoring strategies for intravenous vancomycin use.

Main Methods:

• Review of existing literature and pharmacokinetic principles.
• Proposal for frequent monitoring of both serum and dialysate vancomycin levels.
• Emphasis on balancing systemic safety with adequate intraperitoneal exposure.

Main Results:

• Intravenous vancomycin presents a potential alternative treatment option.
• Therapeutic drug monitoring is essential to guide dosing and ensure efficacy.
• Monitoring serum levels assesses systemic safety, while dialysate levels confirm intraperitoneal exposure.

Conclusions:

• Intravenous vancomycin can be a feasible option for peritoneal dialysis-associated peritonitis where standard treatment is not feasible.
• Pragmatic therapeutic drug monitoring strategies are necessary to optimize treatment outcomes.
• Close monitoring ensures both patient safety and effective antimicrobial activity within the peritoneal cavity.